This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
–(BUSINESS WIRE)– #AD –India Globalization Capital, Inc. (“IGC”) The Data and Safety Monitoring Committee (“DSMC”) for IGC’s clinicaltrial, having reviewed the data obtained through Cohort 1 and Cohort 2, recommended progressing to Cohort 3, which consists of administering three doses per day. POTOMAC, Md.–(BUSINESS
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.
We look forward to his expertise as we expand our mental health analytical platform and enter clinicaltrials. The journey to next-level business growth for Ehave includes adding key advisors.” is a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients. Ehave, Inc.
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.
InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.
MONTREAL & CALGARY, Alberta & TORONTO–(BUSINESS WIRE)– #biotechnology –Knowde Group Inc. , MONTREAL & CALGARY, Alberta & TORONTO–(BUSINESS WIRE)– #biotechnology –Knowde Group Inc. , Extensive early phase experience with appropriate safety oversight and early phase clinic.
–(BUSINESS WIRE)– #IGC –(NYSE American: IGC), India Globalization Capital, Inc. (“IGC” IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinicaltrial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease.
–(BUSINESS WIRE)– #Alzheimers –(NYSE American: IGC), India Globalization Capital, Inc. IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinicaltrial for IGC-AD1. As previously disclosed the recently closed trial was approved to proceed by the U.S.
The Financing will allow the Company to continue progressing its R&D, clinicaltrials and technology initiatives. “I I’m proud of our accomplishments to date and look forward to kicking off multiple clinicaltrials in early 2022,” said CEO, Josh Bartch. DENVER, Dec.
A Windsor, Ontario-based company Audacia Bioscience is especially focussed on three patented technologies that deliver consumer and patient insights to the industry to close the knowledge gaps in the supply chain. Virtual ClinicalTrials transcend geographic, mobility and economic barriers.
The results of our successful pivotal Phase 3 clinicaltrial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.
There are cannabis users, patients, and just everyday fans who may be fans, but don’t make it a big part of their public persona. For these famous medical cannabis patients and supporters, it is something that can improve quality of life and which should be made readily available to anyone in need. 1) Patrick Stewart. It’s tricky.”.
THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.
The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable ClinicalTrials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinicaltrials in the areas of psychedelics and nutraceuticals, among other substances of study.
“Our goal with this study is to enhance the existing treatment’s efficacy through adding CBD to create a new standard of care, potentially improving and extending glioblastoma patients’ quality of life.” Clomiphene will then be added to the regimen for up to 24 patients to rule out toxicity.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a ClinicalTrial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinicaltrial for INM-755 in healthy volunteers. VANCOUVER, Nov.
reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinicaltrials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.
InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.
capital markets, negative global economic conditions, potential negative developments in our clinicaltrials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. Bionomics’ lead drug candidate BNC210 is a negative allosteric modulator of the ?7
11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. Business highlights.
MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp. NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinicaltrials globally. About Flora Growth Corp.
First Patient Expected to be Enrolled by Q2 of 2022. –(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. a leading clinicaltrial services company, for a First in Human study investigating Epoladerm™ for pain associated with osteoarthritis of the knee. BERWYN, Pa.–(BUSINESS
Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . At Veriheal, education and diversity are at the center of our core values.
Following the successful experiment into the potential safety and efficacy of using ketamine for Parkinson’s patients, the university proceeded to sign an exclusive licensing partnership with Pharmather Inc. , Studying Ketamine Use for Parkinson’s Disease Patients. As many as 250 clinics across the U.S.
DUBLIN–(BUSINESS WIRE)–The “Respiratory Health Management Technology Growth Opportunities” report has been added to ResearchAndMarkets.com’s offering. Therapeutic Medical Devices are Preferred by Physicians and Patients for Acute and Chronic Respiratory Conditions. The Strategic Imperative. Research Scope.
–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., This study represents a refreshing collaboration of scientists, clinicians, patients and advocates. Under the Leadership of Nicolas Schlienz, Ph.D., COLORADO SPRINGS, Colo.–(BUSINESS
Similar to ketamine, psilocybin has shown great promise in clinicaltrials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). This post is dedicated to clearing up some of the confusion behind ketamine clinic set-up and operation.
Tetra Bio-Pharma ( TSX: TBP ) ( OTCQB: TBPMF ) ( FRA:JAM1 ) is a leader in cannabinoid-derived drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers.
& LOS ANGELES–(BUSINESS WIRE)– ANANDA Scientific Inc. , Pre-clinical and initial clinical studies show that ANANDA’s Liquid Structure technology (licensed from Lyotropic Delivery Systems (LDS) Ltd. GREENWOOD VILLAGE, Colo. & in Jerusalem, Israel) enhances the effectiveness and stability of CBD.
. – ‘No definitive evidence’ – British charity Versus Arthritis recommends patients contemplating CBD should consult their doctor beforehand, and also wants more work done to understand its impact. ” [link]. . ” [link].
–(BUSINESS WIRE)–The University of Nebraska Medical Center (UNMC) and ANANDA Scientific Inc. OMAHA, Neb. & & GREENWOOD VILLAGE, Colo.–(BUSINESS today announced that. Read More
On December 10 , last year, the bill, which aimed to open prescribing to thousands or UK patients was ‘talked-out’ by the ruling Conservative Party MPs. Cannabis Trials. While it is on the list of Private Members Bills to be heard at today’s parliamentary session there is almost zero chance it will proceed.
BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. Thus, there is a great need to develop new and effective therapeutics for treating patients. Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma.
DUBLIN–(BUSINESS WIRE)– “The Pharmaceutical Cannabis Report: 2nd Edition” report has been added to ResearchAndMarkets.com’s offering. The author has identified at least 30 late-stage clinicaltrials using cannabinoid therapeutics, any of which could have a large impact on the medicinal cannabis space.
The company recently became the industry’s first firm to list on the NYSE American exchange and their psilocybin clinicaltrial for depression is making excellent progress. His background is a mix of cognitive psychology, clinical psychology and computer science. After Approval, It’s Off to Treatment Clinics.
Ketamine Clinics Are an Evolutionary Addition to U.S. Healthcare Ketamine therapy has delivered positive results for patients when used in a structured outpatient setting. In Manhattan alone, 12 clinics have already opened their doors. 0.75mg/kg over 40 minutes) were administered to 100 patients over two weeks.
However, prior to committing to a substantial clinical program for that indication, PharmaDrug looked to further expand on the body of existing supportive data for esophageal cancer, while also potentially revealing new, promising cancer indications. ” Next Steps. Cepharanthine’s Rationale in Cancer. dcohen@pharmadrug.co.
Denmark’s pilot pharma trial attracts first-movers. Europe is open for business, and Denmark wants to be the first-mover. Denmark is already leading the way by launching a Big Pharma modelled 4-year medical marijuana trial in early 2018, following a unanimous vote in Parliament. By Arundati Dandapani. Arundati Dandapani.
According to CAMH’s lead investigator, clinicaltrials suggest that psilocybin, combined with psychotherapy, can produce “ sustained antidepressant effects” in individuals living with severe depression.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content